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Abstract
Background: Astrocytoma is a common aggressive intracranial tumor and presents a formidable
challenge in clinic. Association of the altered DNA methylation pattern of the promoter CpG
islands with the expression profile of the cancer related genes has been found in many human
tumors. Therefore, DNA methylation status as such may serve as the epigenetic biomarker for
both diagnosis and prognosis of human tumors including astrocytoma.
Methods: We used the methylation specific PCR in conjunction with sequencing verification to
establish the methylation profile of the promoter CpG island of thirty four genes in astrocytoma
tissues from fifty three patients (The WHO grading:. I: 14, II: 15, III: 12 and IV: 12 cases,
respectively). In addition, the compatible tissues (normal tissues distant from lesion) from three
non-astrocytoma patients were also included as the control.
Results: Seventeen genes (ABL, APC, APAF1, BRCA1, CSPG2, DAPK1, hMLH1, LKB1, PTEN, p14ARF,
p15INK4b, p27KIP1, p57KIP2, RASSF1C, RB1, SURVIVIN, and VHL) displayed a uniformly unmethylated
pattern in all the astrocytoma and non-astrocytoma tissues examined. However, the MAGEA1 gene
that was inactivated and hypermethylated in non-astrocytoma tissues, was partially demethylated
in 24.5% of the astrocytoma tissues (co-existence of the hypermethylated and demethylated
alleles). Of the astrocytoma associated hypermethylated genes, the methylation pattern of the
CDH13, cyclin a1, DBCCR1, EPO, MYOD1, and p16INK4a genes changed in no more than 5.66% (3/53)
of astrocytoma tissues compared to non-astrocytoma controls, while the RASSF1A, p73, AR, MGMT,
CDH1, OCT6,, MT1A, WT1, and IRF7 genes were more frequently hypermethylated in 69.8%, 47.2%,
41.5%, 35.8%, 32%, 30.2%, 30.2%, 30.2% and 26.4% of astrocytoma tissues, respectively.
Demethylation mediated inducible expression of the CDH13, MAGEA1, MGMT, p73 and RASSF1A
genes was established in an astrocytoma cell line (U251), demonstrating that expression of these
genes is likely regulated by DNA methylation. The AR hypermethylation was found exclusively in
female patients (22/27, 81%, 0/26, 0%, P < 0.001), while the IRF7 hypermethylation preferentially
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occurred in the male counterparts (11/26, 42.3% to 3/27, 11%, P < 0.05). Applying the mathematic
method "the Discovery of Association Rules", we have identified the groups consisting of up to
three genes that more likely display the altered methylation patterns in concert in astrocytoma.
Conclusions: Of the thirty four genes examined, sixteen genes exhibited astrocytoma associated
changes in the methylation profile. In addition to the possible pathological significance, the
established concordant methylation profiles of the subsets consisting of two to three target genes
may provide useful clues to the development of the useful prognostic as well as diagnostic assays
for astrocytoma.
Background
Diffusely infiltrating astrocytoma is a leading group of the
primary central nervous system tumors, accounting for
more than 60% of all primary brain tumors [1,2]. It may
arise aggressively from the normal astrocytes, or evolve
stepwise from the less its benign precursors. Owing to the
difficulties with its early diagnosis and surgical removal of
all residue diseased tissues, rapid progression, and fre-
quent reoccurrence, the most advanced form of astrocy-
toma, glioblastoma (WHO grading IV) represents an
extremely life-threatening intracranial malignant tumor
both inside and outside of China [1,2]. Molecular genetic
analyses have demonstrated multiple genetic lesions
implicating to pathogenesis of astrocytoma, glioblastoma
in particular. In addition to the frequent amplification
and deletion of the EGF receptor gene (EGFR) [3], the
main genetic events affecting the following tumor sup-
pressor genes: the members of the INK4A initiated cell-
cycle arrest pathway (the p16INK4a) [4], the p14ARF [5], the
RB1 [6] and the p53 [7]), a wide spectrum of the cell sur-
face receptor genes (i.e., CD44, integrin, and receptors for
various growth factors), and the PTEN genes [8].
Transcription in eukaryotes is regulated at multiple levels
and inversely correlated with the hypermethylated state as
well as the chromatin condensation. It has been well
established that the methylation status of CpG islands
directly affects the DNA-protein interactions by eliminat-
ing the otherwise occurring sequence specific binding of
the transcription factors whereas inducing the DNA-bind-
ings of members of the methyl-CpG binding protein fam-
ily (MBD). Histone modifications (deacetylation and
methylation) may occur subsequently leading to chroma-
tin condensation and a long-term transcriptional silenc-
ing status of the affected DNA segments. Over 40% of the
protein coding genes have at least one CpG island within
or near to their promoter, an strong indication for tran-
scription of which is likely to be under the control of DNA
methylation status. Three DNA methyl transferases are
involved in the control of the methylation state of the
CpGs in genome. DNA methyl transferase I is mainly
responsible for the maintenance of the methylation status
of the genome after DNA replication, while IIIA and IIIB
act principally in the de novo DNA methylation in the early
development of high eukaryotes. DNA methylation pat-
terns in somatic cells are established during the early
development and contribute to the allele-specific tran-
scription silencing of the imprinted genes, including the
silenced alleles in the X-chromosome and other chromo-
somes. The epigenetic pattern (the DNA methylation pro-
files of the genome) in high eukaryotes is integral to the
normal execution of the biological activities in cells and
needs to be actively maintained. In addition to the
changes linked to the cell lineage specific pattern of gene
expression, both global hypomethylation and local
hypermethylation of the CpG islands occur progressively
as cell ages.
Aberrant DNA methylation pattern changes gene tran-
scription that has been etiologically linked to cancer for-
mation [9,10]. The genome-wide hypomethylation has
been believed to activate transcription of the otherwise
silenced transposon like repetitive sequences (such as the
Alu and LINE repeats in mammals). As a result, the trans-
position occurs more prevalently so that the genomic
instability in cancer cells will be significantly increased
[11-13]. The hypermethylated state of the promoter CpG
islands has been etiologically associated with transcrip-
tion inactivation of a number of tumor suppressor genes
in tumors, which are hypomethylated and transcribed in
their normal counterparts. Therefore, the hypermethyl-
ated CpG island(s) of those genes have been regarded as a
defect, reminiscent to the loss of heterozygosity or other
types of genetic deletion for total inactivation of the
tumor suppressor genes in cancer. The most noticeable
example is the p16INK4a gene that has been frequently
hypermethylated in almost all types of the tumors exam-
ined [14-17] including hepatocellular carcinoma [18].
The loss of the genetic imprinting (changes in DNA meth-
ylation status) has been found to reactivate transcription
of the otherwise silenced allele of the genes such as the
insulin like growth factor 2 gene, which has been well
documented in human tumors [19]. On the other hand,
the reverse process, i.e., demethylation of the promoter
CpG island, has also been found instrumental to the tran-
scription activation of the otherwise inert genes in tumor
cells [20]. A prominent example is the gene encoding the
melanoma antigen, MAGEA1 that was hypermethylatedBMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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and transcriptionally silenced in the normal liver tissues,
and demethylated prevalently in the hepatocellular carci-
noma tissues [18], correlating well with the elevated level
of its expression in HCC [21,22]. The over-expressed gene,
SURVIVIN, has also been reported to be demethylated in
human ovarian cancer [23]. Despite of the fact that the
elevated levels of expression of three DNA methyl trans-
ferase genes were detected in virtually all cancers, the pro-
files of the hypermethylated genes vary with both the
types and stages of cancers. Therefore, the undefined
defects in the epigenetic homeostasis during carcinogene-
sis, rather than the aberrant expression of any given DNA
methyl transferase, are more likely to account for the can-
cer type specific pattern of DNA methylation at both glo-
bal and local levels.
Methylation profiling of the promoter CpG islands has
been an important information gathering process for new
insights into our understanding of the role of DNA meth-
ylation in both initiation and progression of human car-
cinogenesis. It would result in development of the DNA
methylation based assays for cancer diagnosis as well as
identification of the cancer genes suffering from the epige-
netic defects http://www.missouri.edu/~hypermet/
list_of_promoters.htm. However, as the majority of stud-
ies had only targeted one or a few genes in rather small
patient groups, the concurrent hypermethylation behav-
ior of multiple genes has only been addressed in a limited
number of tumor types, such as colorectal cancer. The
majority, if not all, of the previous studies on the astrocy-
toma associated changes in methylation profiles have
only examined a small number of genes for methylation
status at the promoter CpG island [25,26]. In this study,
we determined the methylation profiles of as many as
thirty four genes in a cohort consisting of 53 astrocytoma
patients and established the concordant methylation
behavior of up to three targets. Our observations should
provide new insights into the DNA methylation epige-
netic defects in human astrocytoma.
Methods
All the experiments were performed according to proto-
cols described previously [18]. The primer pairs for the
methylation specific PCR were either adopted (APC,
BRCA1, CDH1, DAPK1, hMLH1, p14ARF, p15INK4b,
RASSF1A, RB1 and VHL) or designed according to the
same principle with assistance of the software packages
for the CpG islands identification http://www.uscnor
ris.com/cpgislands and the primer design http://micro-
gen.ouhsc.edu/cgi-bin/primer3_www.cgi [Additional file
1].
Tissue samples
Tissue samples and DNA preparation
With the informed consent of all patients and approval of
the ethics committee, the tumor samples were collected
from astrocytoma patients (n = 53) during operation at
the Tiantan Neurosurgical Hospital in Beijing. The patho-
logical classification of tumor tissues was carried out and
the stage of each astrocytoma patients was determined
according to the WHO classification [1]. No significant
geographic impart was observed as patients came from
different places in China and went to Beijing for treat-
ment. In addition, the compatible tissues (normal tissues
distant from the lesions) were surgically obtained from
three non-astrocytoma patients [gangliocytoma (21 years
old, male), angiocavernoma (49 years old, male) and
meningioma (54 years old, female)] as the normal con-
trols, which have been subjected to the proper pathologi-
cal evaluation.
Total genomic DNA was extracted from frozen tissue spec-
imens (50 – 100 mg) according to a standard protocol
with some modifications [18,27]. Frozen pulverized pow-
ders of the specimens were re-suspended with 2 ml lysis
buffer: 50 mM Tris-HCl pH 8.0, 50 mM EDTA, 1% SDS,
10 mM NaCl plus 100 µg/ml boiling-treated RNase A
(Sigma). Following one hour of incubation at 37°C, Pro-
teinase K (Roche, USA) was added to the cellular lysates
for a final concentration of 100 µg/ml and the digestion
was carried out at 55°C for 2 hours. Organic extractions
with a half volume of Phenol/Chloroform/Isoamyl alco-
hol (1:1:0.04) were repeatedly carried out until no visible
interphase remained after centrifugation. DNA was pre-
cipitated from the aqueous phase in the presence of 0.3 M
NaOAc pH 7.0 and two and a half volumes of ethanol and
followed by one 70% ethanol-washing and dissolved at
65°C for 30 minutes with 0.2 – 0.4 ml TE (10 mM Tris-
HCl pH 7.4 and 1 mM EDTA)and stored at 4°C till use.
The DNA concentrations were calculated according to the
OD260 nm readings.
Bisulphate treatment of DNA and Methylation specific PCR (MSP)
The methylation status of the promoter CpG islands of
thirty four genes in all DNA samples was analyzed by MSP
on the sodium-bisulfite converted DNA [18]. In detail, 10
µg DNA in 50 µl TE was incubated with 5.5 µl of 3 M
NaOH at 37°C for 10 minutes, followed by a 16 hour
treatment at 50°C after adding 30 µl of freshly prepared
10 mM hydroquinone and 520 µl of freshly prepared 3.6
M sodium-bisulfite at pH 5.0. The DNA was desalted
using a home-made dialysis system with 1% agarose
(detailed protocol will be provided upon request). The
DNA in the desalted sample (approximately 100 µl in vol-
ume) was denatured at 37°C for 15 minutes with 5.5 µl of
3 M NaOH followed by ethanol precipitation with 33 µl 8
M NH4OAC and 300 µl ethanol. After washing with 70%BMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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ethanol, the gently dried DNA pellet was dissolved with
30 µl TE at 65°C for 10 min. The DNA sample was finally
stored at -20°C until further use. PCR reaction was carried
out in a volume of 15 µl with 50 ng or less template DNA
with FastStart Taq polymerase (Roche, Germany) as fol-
lows. After an initial heat denaturing step 4 minutes treat-
ment at 94°C, 30 cycles of 92°C for 15 sec, varying
temperatures with primer pairs (Additional file 1) for 15
sec and 72°C for 20 sec, was carried out. The PCR prod-
ucts were separated by 1.2% ethidium bromide contain-
ing agarose gel electrophoresis with 1 × TAE and
visualized under UV illumination. To verify the PCR
results, representative bands from each target were gel-
purified and cloned into T-vector (Promega, USA) fol-
lowed by automatic DNA sequencing provided by BuoCai
(Shanghai, China). Only verified results are presented in
this report.
To optimize the MSP procedure, the M. Sss I treated DNA
was used as the methylated control template. In detail, the
DNA from a normal liver tissue of the healthy liver donor
[18,24] was batch cleaved with EcoR I, followed by M. Sss
I treatment according to the manufacture's instruction
(New England Biol., Boston, USA) for over night. The
purified DNA was bisulphate treated as usual and sub-
jected to MSP with the primer pairs for each of thirty three
genes (except for the MAGEA1 gene), and only the verified
targets were included for the study of the astrocytoma
tissues.
Statistical analysis
The methylation data were dichotomized as 1 for the co-
existence of the methylated and unmethylated alleles, 2
for methylated allele only and 0 for the unmethylated for
both alleles to facilitate statistical analysis using contin-
gency tables. The methylation profiles of each individual
gene (in percentage) classified by the genders and grading
of the patients were presented both in table and in plot.
The statistic analyses for the association between the
methylation profile of the gene and each of the clinical-
pathological parameters were carried out with the statis-
tics package http://www.R-project.org/, where both Pear-
song's Chi-square test with Upton's adjustment and Fisher
exact test http://www.R-project.org/ were used to examine
the tissue samples with the low expected values. The rela-
tive frequency with a 95% confidence interval (P < 0.05)
for a binomial distribution was calculated for the whole as
well as each subtype of astrocytoma patients.
The concordant methylation behavior of the genes was
established by comparing frequency of co-occurrence of 2
to 3 target subsets with a mathematic method, namely
Discovery of Association Rules [28], which is frequently
utilized for association analysis.
Demethylation of U251 cells with 5-Aza-2'-deoxycytidine
U251 cells (an established glioma cell line) were cultured
in DEME plus 10% new born calf serum at 37°C in a 5%
CO2 atmosphere. When cell culture reached 50% conflu-
ence, they were treated with 5-Aza-2'-deoxycytidine
(Sigma A3656) at the final concentration 10 and 20 nM,
respectively for 3 days. The primer pairs for the RT-PCR
(Table 1) was either adopted from published papers or
designed with an assistance of the software http://micro-
gen.ouhsc.edu/cgi-bin/primer3_www.cgi. The total RNA
was extracted with Trizol solution according to manufac-
turer's instruction (Invitrogen, USA), and cDNA was
obtained using the Supertranscript plus reverse tran-
scriptase with the oligo-dT as primers. PCR with single
pair of the target primers run for 15 cycles, followed by
another 15 cycle PCR reactions in the presence of the beta-
actin primers (Table 1) (the parameter of each cycle is
94°C 20", 60°C for 20" and 72°C for 30"). The resulted
PCR products were visualized under UV illumination after
an electrophoretic separation on a 1.2% agarose. The
methylation status of the target was analyzed by MSP.
Table 1: The primers for RT-PCR analysis
Primer Name sequence PCR Product Length (bp) Accession Number
beta-actin L AAGTACTCCGTGTGGATCGG 616 NM_001101
beta-actin R TCAAGTTGGGGGACAAAAAG
cdh13f GCTGGACTGGATGTTGGATT 246 NM_001257
cdh13t TTGAGGGTTGGTGTGGATTT
magea1rf ACCTGACCCAGGCTCTGT 401 NM_004988
magea1rt CTCACTGGGTTGCCTCTG
mgmtrf AAACGCACCACACTGGAC 404 NM_002412
imgmtrt AGGATGGGGACAGGATTG
p73f AGATGAGCAGCAGCCACAG 218 NM_005427
p73t GTACTGCTCGGGGATCTTCA
rassf1arf GTCTGCCTGGACTGTTGC 401 NM_007182
rassf1art AGCAGGGCCTCAATGACTBMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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Results and discussion
Clinical-pathological classification
To establish the methylation profile of thirty four genes
during the process of astrocytoma development, we
recruited 53 astrocytoma patients (27 female and 26
male; 49 primary and 4 recurrent) for this study. 14 cases
were pathologically classified at the Grade I pilocytic
astrocytoma (10–62 years old, mean: 39.1; 9 female, 5
male), 15 cases at the Grade II diffuse astrocytoma (4–50
years old, mean: 33.1; 10 female, 5 male), 12 cases at the
Grade III anaplastic astrocytoma (1–72 years old; mean:
40.4; 4 female, 8 male), and 12 cases (including 4 recur-
rent cases) at the Grade IV glioblastoma (22–66 years old,
mean: 44.6; SD = 22–66, 4 female, 8 male) (Table 2). The
normal brain tissues distant from the lesions were also
obtained from three non-astrocytoma patients who
underwent brain surgery as normal controls in this study.
Aberrant Methylation profiling in astrocytoma
The technical considerations
The methylation-specific PCR (MSP) is widely used for
methylation profiling of the genes in human cancers for
both its easiness and sensitivity. However, the necessary
steps have to be taken to eliminate both false positive and
negative results. Comparing the MSP-data with the non-
PCR data by Southern analysis of the methylation sensi-
tive restriction enzyme is a valuable choice, as our previ-
ous work where the hypomethylated status of both p14ARF
and p15INK4b  genes shown by MSP was confirmed by
Southern analysis [18]. Alternatively, the PCR reaction
with the in vitro methylated genomic DNA (by M. Sss I) as
template would be an ideal positive control for the
absence of methylated targets in tumor tissue samples. By
taking extra caution, we carried out MSP of all the targets
with the M. Sss I treated normal liver DNA as positive con-
trol templates, except for the MAGEA1 gene was unmeth-
ylated in the normal liver tissue. While only the PCR
reaction designated to the unmethylated template gave
rise to the detectable bands with the parental DNA, the
PCR bands were evident in both reactions with the M. Sss
I treated DNA (Additional File 2). Therefore, failure to
detect the methylated alleles with the tissue samples
should genuinely reflect the lack of methylated targets. To
control the false positive with either pair of primers, the
representative PCR products, were T-cloned and
sequenced. Only the positive PCR results with the
expected sequence profiles were scored and analyzed
further.
The methylation profiling of thirty four targets in astrocytoma
Eleven of the thirty four target genes were previously stud-
ied either in astrocytoma or other types of tumors. The
published PCR conditions for these genes: APC, BRCA1,
CDH1, DAPK1, hMLH1, p14ARF, p15INK4b, p16INK4a
RASSF1A, RB1 and VHL (Additional file 1) were adopted
to enable the relevant inter-study comparisons if neces-
sary. The remaining twenty three targets were selected
from a list of genes http://www.missouri.edu/~hypermet/
list_of_promoters.htm displaying the altered pattern of
the promoter CpG island in various biological settings
including cancers. Their CpG islands were identified via
bioinformatical tools http://www.uscnorris.com/cpgis
lands and the primer pairs were designed accordingly
http://micro-gen.ouhsc.edu/cgi-bin/
primer3_www.cgi[18,24]. Some of these thirty four genes
have been shown to play a role in carcinogenesis, whereas
the others have no obvious association with human car-
cinogenesis. Since it is still disputed whether DNA meth-
ylation mediated the gene silencing is causative in the
malignant transformation of cell, we specifically selected
Table 2: The clinical and pathological profiles of the patients
Astrocytoma Non astrocytoma
Gender
female 27 1
male 26 2
Age, y
<40 27 1
40–60 23 2
>60 3 0
Grade Age
Mean Range
I 39.1 10 to 62 14
II 33.1 4 to 50 15
III 40.4 1 to 72 12
IV 44.6 22 to 66 12
Recurrent 4
Primary 8BMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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both sets of genes in this study. The "cancer unrelated"
genes selected encode erythropoiesis (EPO) [29], a ubiq-
uitously expressed transcription factor (OCT6) [30], and
the myogenesis lineage-specific transcription factor
(MYOD1) [31]. The majority of the cancer associated
genes examined were tumor suppressor genes including
genes operating in the RB1/p16INK4a  pathway (p14ARF,
p15INK4b, p16INK4a, and RB1) [32], and two cyclin-depend-
ent kinase inhibitors (p27KIP1 [33] and p57KIP2) [34]. Other
genes in this subset were a p53 analogue:(p73) [33,35],
two alternative forms of a tumor suppressors in the Ras
mediated signal transduction pathway (RASSF1A, and
RASSF1C [36]), VHL [37], APC [38], PTEN [6], the deleted
in bladder cancer chromosome region candidate 1
(DBCCR1) [39], and the Wilms tumor 1 gene(WT1) [40].
We included the genes encoding the cell membrane pro-
teins or nuclear receptors which act actively in the intercel-
lular interactions: melanoma specific antigen A1
(MAGEA1) [41], caveolin 1 (CAV) [42], chondroitin sul-
fate proteoglycan 2 (CSPG2) [43], androgen receptor (AR)
[44], and cadherins (CDH1 [45] and CDH13) [46]. Three
genes implicated in signal transduction were also selected:
cyclin a1 [47], the interferon regulatory factor 7 (IRF7),
and a serine/threonine kinase 1 (Peutz-Jeghers syndrome)
gene (LKB1) [14]. There were the genes encoding the O-6-
methylguanine-DNA methyltransferase (MGMT) [14]and
metallothionein 1 A gene (MT1A) [48] which play a key
role in the cellular response to alkalyting agents and heavy
metal stress. The genes acting in DNA repair process were
hMLH1  [49], and BRCA1  [50], while four genes are
involved in apoptosis (APAF1  [51],  DAPK1  [15], and
SURVIVIN  [23]). Finally, the proto-oncogenes in this
group were represented by v-abl homologue 1 (ABL) [52]
(Additional files 3,4,5,6,7,8,9).
The genes displayed the uniformly unmethylated profiles in 
astrocytoma
Of the unmethylated genes in all samples tested, EPO was
a cancer unrelated gene, while "cancer associated" genes
included ABL(1), APAF1(2), APC(3), BRCA1(5), CAV(6),
CDH13(8),  DAPK1(11),  hMLH1(14),  LKB1(16),
p14ARF(22), p15INK4b(23), p27KIP1(25), p57KIP2(26), PTEN
(28),  RASSF1C(30),  RB1(31),  SURVIVIN(32), and
VHL(33) genes (Additional files 3,4,5,6,7,8,9).
Lack of hypermethylation of the RB1 gene in our observa-
tion was inconsistent with a recent report that the hyper-
methylated RB1 gene was detected in 19% of astrocytoma
patients (26/136 cases analyzed) [53]. Since the same
region was looked at in this work, the discrepancy noticed
may simply reflect the inherent difference in the patient
cohorts between our work and the published [53].
The genetic defects affecting the PTEN gene contributed to
the pathogenesis of astrocytoma [54]. Lack of the hyper-
methylation of its promoter CpG island in both normal
and astrocytoma tissues indicates that the DNA hyper-
methylation mediated silencing mechanism unlikely
plays a significant role in the PTEN  inactivation that
occurs frequently in astrocytoma. This explanation might
also be applicable to the no change type of methylation
behavior for both the tumor associated genes (ABL(1),
APAF1(2),  APC(3),  BRCA1(5), CAV(6), CDH13 (8),
DAPK1(11), hMLH1(14), LKB1(16), p14ARF(22),
p15INK4b(23),  p27KIP1(25),  p57KIP2(26),  PTEN  (28),
RASSF1C(30),  RB1(31),  SURVIVIN(32), and VHL(33)
genes) and the "cancer unrelated" genes (EPO  (14))
(Additional files 3,4,5,6,7,8,9).
The genes with the astrocytoma specific alteration in methylation
As shown in Additional files 3,4,5,6,7,8,9, thirteen genes
(CDH1  (7),  CSPG2(9),  cyclin a1(10),  DBCCR1(12),
IRF7(15),  MGMT(18),  MT1A(19),  MYOD1(20),
OCT6(21),  p16INK4a (24),  p73(27),  RASSF1A  (39) and
WT1(34)) were unmethylated in all three normal con-
trols. In contrast, these genes were hypermethylated to
various extents in the astrocytoma samples. The following
six genes were marginally hypermethylated: p16INK4a,
EPO, DBCCR1 and MYOD1 genes were hypermethylated
in 1.9% (1/53) of astrocytoma tissues, while both CDH13
and cyclin a1 genes were hypermethylated in 5.7% (3/53)
of astrocytoma cases. No significant changes of these six
genes shown in here acted against the notion that DNA
methylation related mechanisms underline potential
inactivation of this set of genes in the pathogenesis of
astrocytoma. The infrequent hypermethylation of the
p16INK4a gene in astrocytoma was a total surprise, as it was
frequently reported hypermethylated in various human
tumors tested, including in HCC where we have previ-
ously found that the p16INK4a, MYOD1, CDH13 and cyclin
a1 genes were frequently methylated [18,24]. To further
verify this unexpected observation, we repeated the MSP
analysis on five astrocytoma samples (shown unmethyl-
ated) along with one HCC sample (previously shown het-
erozygously methylated). As shown in panel 1, Fig. 1, MSP
patterns of the astrocytoma as well as HCC tissues
remained the same. The identities of which were also con-
firmed by sequencing (panel 2, Fig. 1), showing that while
the MSP products with the primers specific to the methyl-
ated targets in the HCC sample (Z92K) contained CpGs,
the unmethylated targets in all the five astrocytoma tissues
(21, 22, 26, A11 and B6) contained TpGs. Therefore, lack
of hypermethylation of the p16INK4a gene in astrocytoma
was unlikely incorrect, which is consistent with a recent
report that inactivation of the p16INK4a gene in 48% of
astrocytoma cases was genetic [55].
The remaining 7 targets were hypermethylated more fre-
quently, occurring in 26.4% to 69.8% (14 to 37/53) of
astrocytoma cases. The OCT6 gene was hypermethylatedBMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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in 30.2% of the astrocytoma cases (16/53). Despite of the
association of the OCT6 methylation with the aging proc-
ess reported previously, we found no significant correla-
tion/association of the OCT6 methylation to any clinical-
pathological features, including age, gender and clinical
grading of the patients. The significance of such a preva-
lent occurrence of the hypermethylated OCT6  gene
remains to be determined. The RASSF1A (hypermethyl-
ated in 37/53 cases, 69.8%) is a variant of the recently
identified tumor suppressor, the RASSF1 gene that acts at
downstream of the Ras mediated apoptotic pathway and
is capable of binding to Ras in a GTP dependent manner
[36]. The RASSF1A gene has a more extended 5' part and
its promoter CpG island displays a tumor specific hyper-
methylated profile in a variety of tumors, HCC in particu-
lar. Furthermore, lack of the RASSF1A expression in
nineteen established tumor cell lines correlates with the
hypermethylated state of its promoter CpG island [36].
The RASSF1C gene has its own promoter CpG island, but
is not methylated in any tumors. The methylation behav-
ior of these two genes was very similar to our previous
observation in hepatocellular carcinoma, where 22/29
cases (79%) had the fully methylated 1A along with the
unmethylated 1C variants [18]. As shown in Additional
file 4,5,6,7,8,9, the RASSF1A promoter-CpG island was
methylated in 69.8% (37/53) of astrocytoma tissues,
while the C variant was not methylated in any astrocy-
toma tissues. The hypermethylated state of the RASSF1A
promoter CpG island was not correlated with gender, age
and clinical grading. Consistent with the hypermethylated
status of the RASSF1A gene in U251 cells, no expression at
the mRNA level was detected. Partial demethylation of its
promoter by the treatment with 5-Aza-2'-deoxycytidine
indeed resulted in its transcription (Fig. 2).
MSP/sequencing analyses of the p16INK4a gene in astrocytoma and hepatocellular carcinoma Figure 1
MSP/sequencing analyses of the p16INK4a gene in astrocytoma and hepatocellular carcinoma Both electrophoretic patterns of 
the PCR products of the p16INK4a in each of five astrocytoma cases (21, 22, 26, A11 and B6) and one HCC case (Z92K) (indi-
cated respectively, at the top of figures) were presented. To indicate the methylation status, the sequenced data are aligned 
with the wild-type sequence.BMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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The p73 gene encodes a homologue to TP53, and loss of
its heterozygosity has been observed in up to 90% of oli-
godendrogliomas and in 10–25% of diffuse astrocytoma
[56,57]. In this study, we found that the p73 gene was
prevalently methylated (25/53, 47.2%) with no signifi-
cant association with any clinical-pathological parame-
ters, such as gender and the WHO grading. The occurrence
of the hypermethylated p73 gene was more prevalent in
our results than a recent report which detected the hyper-
methylated p73 gene in 18% (5 /28) of the WHO grade IV
but not in grade III astrocytoma [35]. Again, even the par-
tially elevated demethylated status of its promoter CpG
island in U251 cells resulted in reactivation of p73 tran-
scription (Fig. 2).
Both genetic defects and epigenetic abnormalities of the
WT1 gene have been etiologically implicated in the for-
mation of the Wilm's tumor [58]. In this study, we also
found that the WT1 gene was hypermethylated in 30%
(16/53) of cases, implying its possible involvement in the
formation of astrocytoma.
Tumor resistance to the cytotoxic chemotherapies may
result from the disrupted apoptosis programs and remains
The methylation state and expression profiles of the CDH13, p73, MAGEA1, MGMT and RASSF1A genes in U251 astrocytoma  cells before and after the demethylation treatment with 5-Aza-2'-deoxycytidine Figure 2
The methylation state and expression profiles of the CDH13, p73, MAGEA1, MGMT and RASSF1A genes in U251 astrocytoma 
cells before and after the demethylation treatment with 5-Aza-2'-deoxycytidine U251 cells were subjected to the 10 and 20 nM 
5-Aza-2'-deoxycytidine (5-Aza) treatment for 3 days before both DNA and RNA were prepared for either MSP analyses or 
RT-PCR assessments. Panels; A, the methylation status of the CDH13, p73, MAGEA1, MGMT and RASSF1A genes and B, the 
expression profiles of each of these five genes, respectively in U251 cells.BMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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a major obstacle in cancer treatment. In this study, the
interferon regulatory factor 7 (IRF7) gene was analyzed.
The analogue (IRF1) of IRF7 has been implicated in the
IFN gamma mediated apoptosis with a profound effect on
the chemo-sensitivity of tumor cells [59,60]. In consist-
ence with the recent report that the IRF7 expression was
negatively regulated by the promoter methylation [61],
we found that the IRF7 gene was hypermethylated in
astrocytoma (14/53, 26.5%) (Additional file 4,5,6,7,8,9),
with a strong male inclination (11/26, 42.3% verse the
female group: 3/27, 11%, χ2 = 6.632, P = 0.014). Although
the gender difference remains to be understood, such a
strong male association with IRF7 hypermethylation may
have prognostic value.
O(6)-methylguanine-DNA methyltransferase (MGMT), a
DNA repair enzyme, removes alkylating adducts from the
O(6) position of guanine and protects cells from cytotoxic
and mutagenic stress. Silencing of the MGMT gene has
been suggested to predispose the neoplastic clones to
acquisition of the guanine to adenine point mutations in
K-ras and p53 [62] and is associated with low-levels of
micro-satellite instability in colorectal cancer [63]. We
found that the MGMT gene was prevalently hypermethyl-
ated in astrocytoma (35%, 19/53), and its transcription
could be reactivated by demethylation with 5-Aza-2'-
deoxycytidine in U251 cells (Fig. 2). Hence, the MGMT
hypermethylation in astrocytoma may indeed have the
pathological significance. In this connection, a recent
report suggested that the astrocytoma sensitivity to the
alkylating type of chemotherapeutics might be contrib-
uted by the hypermethylated MGMT gene [64]. Expres-
sion of the metallothionein I A (MT1A) is inducible by a
number of adversary agents such as heavy metals and oxi-
dative stress. Both basal and inducible expression of this
gene has been impaired in various tumor cell lines and
attributed to the hypermethylated state of this gene [48].
In this study, we found that the MT1A gene was hyper-
methylated in 30% (16/53) of cases, with no significant
gender and grading difference. The functional and
pathological implications of the MT1A hypermethylation
in astrocytoma remain to be established.
Cadherins, the calcium-dependent proteins, contribute to
various biological processes such as differentiation,
migration and extra-cellular signal transduction of cell.
Loss of expression of both E-cadherin (CDH1) and H-cad-
herin (CDH13) has been found in parallel with the hyper-
methylated promoter CpG islands in various cancers
[65,66]. In this study, we found that the CDH1 gene was
hypermethylated in 32.8% (17/53) of astrocytoma tis-
sues, while the CDH13 gene was not methylated in all the
astrocytoma tissues examined (Additional files
4,5,6,7,8,9). In contrast, in human hepatocellular carci-
noma [18], the CDH1 gene was unmethylated, while the
CDH13 gene was frequently hypermethylated. Obviously,
the molecular basis for tumor type specific methylation
patterns of these two genes remains to be determined.
Although the hypermethylation mediated gene silencing
of the tumor suppressor genes is at the focal point of the
epigenetic studies, demethylated status of the promoter
CpG islands has been linked to the tumor associated acti-
vation of the normally silenced genes [19-23]. Therefore,
we also studied both MAGEA1 and SURVIVIN genes. The
promoter CpG islands were hypermethylated in normal
tissues (for MAGEA1 in HCC [18] and for SURVIVIN in
ovarian cancer [23]) and demethylated in parallel with
the transcriptional activation in tumor cells. The
unmethylated status of the SURVIVIN  gene in astrocy-
toma is consistent with the over-expression of this gene
(unpublished observations). However, its unmethylated
status in all the non-astrocytoma tissues acts odd with the
notion that its demethylation is associated with pathogen-
esis in human ovarian cancer reported previously [23].
Our previous studies indicated that demethylation of the
promoter CpG island was correlated well with the over-
expression profile of the MAGEA1 gene [18,21] in HCC.
The MAGEA1 gene was fully hypermethylated in all four
cases of the normal liver tissues but significantly demeth-
ylated in HCC tissues (21/28, 75%). It was found fully
hypermethylated in all the three control tissues and in
74.5% (40/53) of the astrocytoma tissues and partially
hypermethylated (13/53, 25.5%) in the other
astrocytoma tissues. The occurrence of the MAGEA1
demethylation in HCC differed significantly from astrocy-
toma (75% verse 25.5%, P < 0.001). As it was fully meth-
ylated in the normal tissue, the partial hypermethylation
(both hypermethylated and demethylated alleles existed)
would imply that the event resulting in the loss of the
hypermethylation state of the MAGEA1  gene indeed
occurred in astrocytoma and should be scored positive for
the changes in the methylation pattern in this study. The
same principle has been applied for the opposite changes
from the unmethylated pattern in the normal control to
the partial or full hypermethylated status of all the other
genes in astrocytoma tissues. It was also found that the
partial demethylated status of the MAGEA1 gene in U251
cells induced by 5-Aza-2'-deoxycytidine occurred co-cur-
rently with activation of its transcription (Fig. 2).
The gender association of the methylation profiles of the AR and IRF7 
gene in astrocytoma
By statistic analysis with both Pearson Chi-Square and
Fisher's Exact tests, associations of the DNA methylation
profiles of the targets displaying no less than 24.5%
changes (the RASSF1A, p73, MGMT, CDH1, OCT6, WT1
as well as MAGEA1 genes) with the clinical pathological
parameters (age, grading and gender) were assessed. TheBMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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methylation profiles of the AR and IRF7 genes were found
gender-oriented.
The AR gene encodes the androgen receptor that plays a
key role in the signal transduction pathways in response
to the male steroid hormone, androgen and has been
reported to be inactivated via the epigenetic mechanism
in prostate cancers [67]. Physiologically, the AR gene
should express exclusively in the somatic cells in males,
while lacking of its expression in females is likely medi-
ated by DNA methylation based mechanisms. Indeed, the
hypermethylated along with the unmethylated AR genes
were only found in the normal female brain tissue, but
not from two male non-astrocytoma samples. The hyper-
methylation of the AR gene occurred frequently in the
female group (81.5%, 22/27) but not in any males (0%,
0/26, χ2 = 36.22, P = 0.000). It may simply be gender asso-
ciated and do not have any significant relevance to car-
cinogenesis of astrocytoma. It was also noticed that
hypermethylation of the IRF7 gene displayed an opposite
gender inclination, detected in 11% of the female patients
(3/27), and 42% of male patients (11/26, χ2 = ?6.632, P =
0.014). Despite of the difficulty to offer a mechanistic
interpretation, the potential prognostic value of such a
gender-associated phenomenon might be worthwhile
exploring in future.
Demethylation by 5-Aza-2'-deoxycytidine treatment of the 
astrocytoma cells in culture resulted in partial demethylation and 
reactivated expression of the genes
The hypermethylated status of the promoter CpG island
has been linked to gene transcription silencing in a
number of biological settings. The effect of the astrocy-
toma associated changes in the methylated state of the
promoter CpG islands detected in this study on gene
expression was assessed in U251 astrocytoma cells treated
with the a demethylating agent, 5-Aza-2'-deoxycytidine.
We used MSP to establish the methylation status of the
promoter CpG island of all the genes with the astrocy-
toma associated methylation changes (Additional files
3,4,5,6,7,8,9) in U251 astrocytoma cells, and analyzed
the ability of 5-Aza-2'-deoxycytidine to demethylate five
genes, as measured by MSP, and reactivate their expres-
sion, as detected by RT-PCR.
As shown in panel 1 of Fig. 2, while the CDH13, MAGEA1
and  p73  genes were heterozygously methylated, both
MGMT and RASSF1A genes were fully hypermethylated in
U251 cells. The CDH13 gene was found expressed, while
the rest transcriptionally inert as measured by the RT-PCR.
Although both methylated and unmethylated alleles for
p73  and  MGMT  genes were evident in U251 cells, no
expression was detected, indicating that the unmethylated
allele may remain silent by the other mechanisms, includ-
ing the genetic defects at critical control region. By the 5-
Aza-2'-deoxycytidine treatment, both demethylation of
the promoter CpG island and activation of transcription
of these five genes were achieved (Fig. 2). Despite of the
fact that demethylation of the promoter CpG islands was
incomplete in samples treated with 20 nM 5-Aza-2'-deox-
ycytidine (Fig. 2), the expression of this five genes was
either induced (the MAGEA1, MGMT, p73 and RASSF1A
genes) or elevated (the CDH13 gene).
The concordant methylation behavior of the promoter CpG islands of 
the genes in Astrocytoma
The DNA methylation mediated epigenetic changes also
display the tumor type specific patterns, which seem to
reflect the differentiation and maturation histories of the
cell lineages as well as the aging process during which
both global hypo- and local hyper-methylation occur.
Hypermethylation of the promoter CpG islands in accord
with the transcriptional silencing of the tumor suppressor
genes, such as the p16INK4a, and RASSF1A genes, has been
well established in human tumors [16,68]. However, it
remains unclear whether there is a common mechanism
for the concurrent methylation changes of multiple tumor
suppressor genes in tumors. To address this matter, it is
necessary to examine a large number of genes for frequent
changes in methylation in any type of human tumors. The
concordant methylation behavior of multiple genes was
firstly detected in colon cancer [69], based upon a
comprehensive methylation profiling of over thirty genes.
In this study, we have profiled the methylation status of
thirty four genes in a cohort of 53 astrocytoma and 3 non-
astrocytoma patients. Twenty three of these genes had not
been studied previously in astrocytoma. As far as the
number of the genes is concerned, this study is the most
extensive in the astrocytoma field to our knowledge.
Among thirty four genes, sixteen genes exhibited the
astrocytoma associated changes in methylation profiles of
the promoter CpG islands and nine genes displayed rather
frequent changes (the occurrence ≥ 13/53, frequency ≥
24.5%) (Additional file 8).
Four of 53 cases (7.5%) maintained the same methylation
profile as the normal control. The rest 49 cases (92.5%)
suffered from the methylation changes as much as no less
than one target, an occurrence was significantly lower
than in HCC, where all the cases displayed methylation
changes affecting no less than three targets in the studies
involved with twenty or twenty four targets [18,24], indi-
cating that alterations in DNA methylation \occur more
frequently in HCC than in astrocytoma. This may be con-
tributed by the apparent anatomic inaccessibility of the
brain to environmental adverse factors in comparison to
the liver. The size of the subsets containing various
number of the target affected (from one to nine) ranged
from 1 to 11 cases, and peaked with 10 cases at three and
11 cases at five target subsets (Additional file 9). To iden-BMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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tify the most frequent changes of the target sets (one to
three), a mathematic method called "the Discovery of
Association Rules" [28] was used. The co-occurrence (case
number/the total) and frequency (% of the total) of any
subset of the targets that changed in methylation together
in astrocytoma were counted and compared. In the entire
cohort of patients in this study, the most altered target was
the RASSF1A gene, 69.8% (37/53). The two genes that
most altered together were the RASSF1A and p73 genes,
hypermethylation of which was found in 20 (37.7%).
Three genes that changed together were the former two
plus CDH1 or OCT6, hypermethylation of which occurred
in 20.8% cases (11/53) (Column 2, a, Additional file 10).
Furthermore, the occurrence in methylation change in any
target in the two gene subsets was 79.3% (42/530 and in
three gene subsets was 81.1–83% (43–44/53) (Column 3,
a, Additional file 10).
Since the hypermethylated AR is associated closely with
the female gender of the astrocytoma patients and devoid
of any association with the formation of astrocytoma, it
was taken out from this analysis. Hypermethylation of the
RASSF1A gene occurred in 21 female cases (77.8%, 21/
27). Both RASSF1A and WT1 were hypermethylated in 13
(13/27, 48.1%); and the former two plus the hypermeth-
ylated p73 or CDH1 or OCT6 were found in 9 female cases
(9/27, 33.3%), respectively (Column 2, b, Additional file
10). The subsets in the male patient group showed very
different patterns. The single to three target subsets were
the RASSF1A (16/26, 61.5%); the RASSF1A and IRF7 (10/
26, 38.5%); and the former two plus the p73 or MGMT or
MT1A (5/26, 19.2%), respectively (c, Additional file 10).
In Grade I astrocytoma, the subsets for one, two and three
targets were RASSF1A (10/14, 71.4%), RASSF1A plus p73
(6/14, 42.9%), and the former two plus either WT1 or
IRF7 or MAGEA1 as well as RASSF1A plus CDH1 and WT1
(3/14, 21.4%). For Grade II astrocytoma, the correspond-
ing sets consisted of the RASSF1A  (12/15, 80%), the
RASSF1A  and  MGMT  or  IRF7  (5/15, 33.3%), and the
RASSF1A and MGMT plus p73 or OCT6, or MT1A, or WT1
as well as the RASSF1A and IRF7 and MT1A (3/15, 20%),
respectively. For Grading III astrocytoma, those subsets
were composed of the RASSF1A  (8/12, 66.7%), the
RASSF1A and CDH1 (5/12, 41.7%), and the formal two
plus MGMT (4/12, 33.3%), respectively. For Grading IV
astrocytoma, the comparative subsets contained the
RASSF1A or p73 (7/12, 58.3%), the RASSF1A and p73 (6/
12, 50%), and the former two plus MGMT or OCT6 (4/12,
33.3%), respectively. (d-g, Additional file 10).
Our methylation profiling efforts described in this report
provided the following informative targets: the RASSF1A,
p73, WT1, MGMT, CDH1, OCT6, and IRF7  genes. The
established concordant methylation profiles of these eight
genes (Additional file 10) may provide useful clues for the
epigenetic biomarker selection to for the novel diagnostic
and prognostic assays of astrocytoma. The hypermethyl-
ated status of this lest of genes in the serum, and biopsies
of the suspected astrocytoma patients may serve as good
diagnostic indicators, if they can be reliably detected.
With the death/survival profiles of this cohort of astrocy-
toma patients available in the future, the methylation pro-
file established in this study may have certain prognostic
value.
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Additional material
Additional File 1
The target promoter CpG islands and the primer pairs for methylation spe-
cific PCR. This file contains his study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-65-S1.pdf]
Additional File 2
Methylation profiles of thirty three genes on the in vitro methylated 
genomic DNA by M. Sss I methyl transferase. The Eco RI restricted 
genomic DNA from the liver tissue of a healthy donor was in vitro meth-
ylated overnight with M. Sss I methyl transferase and subjected to the 
MSP analysis, followed by electrophoresis in a 1.3% agarose gel. *, the 
DNA size markers, NL, the untreated sample, U and M, MSP with the 
pair of primers specific to the unmethylated and methylated targets, 
respectively. Panels: 1, ABL; 2, APAF1; 3, APC; 4, AR; 5, BRCA1; 6, 
CAV; 7, CDH1; 8, CDH13; 9, CSPG2; 10, cyclin a1; 11, DAPK1; 12, 
DBCCR1; 13, EPO; 14, hMLH1; 15, IRF7; 16, LKB1; 17, MGMT; 18, 
MT1A; 19, MYOD1; 20, OCT6; 21, p14ARF; 22, p15INK4b; 23, 
p16INK4a; 24, p27 KIP1; 25, p57KIP2; 26, p73; 27, PTEN; 28, RASSF1A; 
29, RASSF1C; 30, RB1; 31, SURVIVIN; 32, VHL and 33, WT1.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-65-S2.pdf]
Additional File 3
Methylation profiles of thirty four genes in astrocytoma (part I). Both elec-
trophoretic patterns of the representative PCR products of each of thirty 
four targets (indicated respectively, at the top of figures) and the sequenc-
ing verification of the one representative PCR product were presented. To 
indicate the methylation status, the sequenced data are aligned with the 
wild-type sequence. *, size markers, the bands of 250 bp and 100 bp were 
shown. U, the unmethylated; M, the hypermethylated. Panels: 1, ABL; 2, 
APAF1; 3, APC; 4, AR; 5, BRCA1; 6, CAV; 7, CDH1; 8, CDH13; 9, 
CSPG2; 10, cyclin a1; 11, DAPK1 and 12, DBCCR1.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-65-S3.pdf]
Additional File 4
Methylation profiles of the promoter CpG islands of thirty four genes in 
astrocytoma (part II). Both electrophoretic patterns of the representative 
PCR products of each of thirty four targets (indicated respectively, at the 
top of figures) and the sequencing verification of the one representative 
PCR product were presented. To indicate the methylation status, the 
sequenced data are aligned with the wild-type sequence. *, size markers, 
the bands of 250 bp and 100 bp were shown. U, the unmethylated; M, 
the hypermethylated. Panels: 13, EPO; 14, hMLH1; 15, IRF7; 16, LKB1; 
17, MAGEA1; 18, MGMT; 19, MT1A; 20, MYOD1; 21, OCT6 and 22, 
p14ARF>.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-65-S4.pdf]
Additional File 5
Methylation profiles of the promoter CpG islands of thirty four genes in 
astrocytoma (part III). Both electrophoretic patterns of the representative 
PCR products of each of thirty four targets (indicated respectively, at the 
top of figures) and the sequencing verification of the one representative 
PCR product were presented. To indicate the methylation status, the 
sequenced data are aligned with the wild-type sequence. *, size markers, 
the bands of 250 bp and 100 bp were shown. U, the unmethylated; M, 
the hypermethylated. Panels: 23, p15INK4b; 24, p16INK4a; 25, p27 KIP1; 
26, p57KIP2; 27, p73; 28, PTEN; 29, RASSF1A; 30, RASSF1C; 31, RB1; 
32, SURVIVIN; 33, VHL and 34, WT1.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-65-S5.pdf]
Additional File 6
The summary of the astrocytoma cases displaying no or changes in the 
methylation profiles (part I). The frequency (%) of the astrocytoma dis-
playing no or the changes in the methylation profile of each target from 
the normal control were counted and presented in table as well as plotted 
in the figure below. The filled, shading and empty boxes indicate the cases 
where only hypermethylated allele, both hypermethylated and unmethyl-
ated alleles and only unmethylated alleles were detected, respectively. The 
frequency (%) of the hypermethylated targets (except for the MAGEA1 
gene) among the total cases was scored for positive changes in astrocy-
toma. The MAGEA1 was fully methylated (3/3, 100%) in the control, 
and become partially demethylated in some astrocytoma, therefore, 
demethylation of the MAGEA1 in astrocytoma was scored as positive 
changes. Sub-tables: a, the female patient group, b, the male patient 
group, and c, the control.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-65-S6.pdf]
Additional File 7
The summary of the astrocytoma cases displaying no or changes in the 
methylation profiles (part II). The frequency (%) of the astrocytoma dis-
playing no or the changes in the methylation profile of each target from 
the normal control were counted and presented in table as well as plotted 
in the figure below. Sub-tables d-h, the WHO grading I to IV, respectively; 
The filled, shading and empty boxes indicate the cases where only hyper-
methylated allele, both hypermethylated and unmethylated alleles and 
only unmethylated alleles were detected, respectively. The frequency (%) 
of the hypermethylated targets (except for the MAGEA1, where the heter-
ozygously hypermethylated) among the total cases was presented in the 
plot.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-65-S7.pdf]
Additional File 8
The occurrences and frequency of changes in methylation. *, One of three 
cases was methylated; **, The MAGEA1 gene was fully methylated in the 
normal tissues and partially demethylated in astrocytoma patients as indi-
cated in the relevant cells. Therefore, the astrocytoma associated changes 
in methylation of this gene is opposite to the rest, i.e., demethylation rather 
than hypermethylation. Figure is each cells are the frequency in % and 
occurrence (case number).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-4-65-S8.pdf]BMC Cancer 2004, 4:65 http://www.biomedcentral.com/1471-2407/4/65
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